Analysts Are Neutral on These Healthcare Stocks: Innoviva (INVA), Arvinas Holding Company (ARVN)
Analysts fell to the sidelines weighing in on Innoviva (INVA – Research Report), Arvinas Holding Company (ARVN – Research Report) and Revolution Medicines (RVMD – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Innoviva (INVA)
In a report released today, Trevor Allred from Oppenheimer downgraded Innoviva to Hold, with a price target of $35.00. The company’s shares closed last Wednesday at $24.24.
According to TipRanks.com, Allred is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Innoviva with a $36.75 average price target, which is a 56.9% upside from current levels. In a report released today, TipRanks – Anthropic also downgraded the stock to Hold with a $27.00 price target.
See the top stocks recommended by analysts >>
Arvinas Holding Company (ARVN)
Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Arvinas Holding Company today. The company’s shares closed last Wednesday at $13.30.
According to TipRanks.com, Biegler is a 4-star analyst with an average return of
Arvinas Holding Company has an analyst consensus of Moderate Buy, with a price target consensus of $16.44, representing a 26.7% upside. In a report released yesterday, TipRanks – Google also downgraded the stock to Hold with a $12.50 price target.
Revolution Medicines (RVMD)
Revolution Medicines received a Hold rating and a $150.00 price target from Oppenheimer analyst Jay Olson today. The company’s shares closed last Wednesday at $103.24.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $139.42 average price target, representing a 31.7% upside. In a report released today, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $108.00 price target.
